The purpose of this research study is to determine if consuming arctigenin, a natural compound from a Chinese herb called Arctium lappa (commonly called greater burdock), is safe, and to measure the intake level of arctigenin in blood. Arctigenin is being studied by researchers for potential health benefits such as helping to lower the risk of inflammation and cancer. A human study has been done measuring the uptake of arctigenin into blood after consumption of the herb extract containing arctigenin, and found no toxicity. Studies in mice demonstrated that consumption of arctigenin in pure form at a safe level is highly effective in inhibition of prostate cancer growth. Therefore, this study is designed to evaluate the safety and uptake rate of pure arctigenin in humans, which may be potentially used in the future for prostate cancer prevention.

开始日期2019-01-15

申办/合作机构

University of California, Los Angeles

[+1]

JPRN-UMIN000010111

/ Completed临床2期IIT

Phase 2a trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine and fluoropyrimidine chemotherapy.

开始日期2013-03-11

申办/合作机构

National Cancer Center Hospital East

JPRN-UMIN000005787

/ CompletedN/AIIT

Phase 1/2 study of GBS-01 in patients with gemcitabine-refractory advanced pancreatic cancer.

开始日期2011-06-01

申办/合作机构

National Cancer Center Hospital East

100 项与 Arctigenin 相关的临床结果

登录后查看更多信息

100 项与 Arctigenin 相关的转化医学

登录后查看更多信息

100 项与 Arctigenin 相关的专利（医药）

登录后查看更多信息

1,752

项与 Arctigenin 相关的文献（医药）

2026-12-31·Virulence

Synergistic antibacterial activity and mechanism of arginine combined with florfenicol against Escherichia coli

Article

作者: Liu, Hanyu ; Li, Yuhang ; Li, Yanhua ; Xiong, Shanshan ; Liu, Xiaona ; Zhao, Menghan ; Su, Yuefan ; Cao, Mingyu ; Dong, Chunliu ; Han, Guangfu

The persistent escalation of antibiotic resistance poses a severe threat to global public health. As a common opportunistic pathogen, the rapid development of resistance in Escherichia coli (E. coli) poses severe challenges to clinical anti-infective therapy. Against this backdrop, the combined use of amino acids and antibiotics is considered an effective strategy against multidrug-resistant bacterial infections. This study investigated the antibacterial efficacy and mechanism of action of the combination of arginine (Arg) and florfenicol (FFC) against resistant E. coli. Results indicate that Arg significantly enhances the bactericidal activity of FFC against resistant E. coli both in vivo and in vitro, successfully reversing the resistance phenotype. Mechanistic studies reveal that Arg disrupts fatty acid β-oxidation by inhibiting the arginine succinyl-transferase (AST) pathway, leading to excessive free fatty acid (FFA) accumulation. This triggers membrane structural damage, energy metabolism disorders, and oxidative stress. Concurrently, Arg inhibits the expression and function of multidrug efflux pumps, such as AcrAB-TolC and EmrAB-TolC, reducing FFC efflux and increasing its intracellular concentration. This study systematically reveals a novel pathway whereby Arg synergistically enhances the antibacterial activity of FFC through dual mechanisms of metabolic reprogramming and efflux pump inhibition, providing theoretical support for the development and application of amino acid compounds as antibiotic adjuvants.

2026-09-01·Infection Disease & Health

Health-related quality of life and its predictors in cancer patients with antimicrobial-resistant infections: A prospective study

Article

作者: Chauhan, Richa ; Priya, Pallavi ; Shelke, Akshay ; Dhingra, Sameer

BACKGROUND:

Antibiotic-resistant infections are known to pose a significant challenge to cancer patients, with increased morbidity, mortality and financial burden; however, less is known about their potential impact on health-related quality of life (HRQoL) in this population. This study aimed to assess HRQoL, its predictors, and quality-adjusted life years (QALYs) in cancer patients with antimicrobial-resistant infections (ARG) compared to those with antimicrobial-sensitive infections (ASG) and no infection.

METHODS:

A prospective cohort observational study was conducted among (N = 657) hospitalized adult cancer patients categorized into three groups: no infection (n = 150), ASG (n = 159), and ARG (n = 348), for 18 months. HRQoL was assessed using the EQ-5D-5L tool.

RESULTS:

Patients with ARG reported lower HRQoL, with a mean utility score of 0.391 and EQ-VAS score of 41.79, compared to ASG (0.468; 49.31) and no infection (0.533; 55.39) (P < 0.001). However, multidrug-resistant (MDR) and extensively drug-resistant (XDR) groups demonstrated significantly lower HRQoL scores (utility: 0.417 & 0.372; EQ-VAS: 44.3 & 40.02) than ASG. QALYs declined progressively (no infection: 0.046, sensitive: 0.036, resistant: 0.025; p < 0.001). MDR & XDR infections were associated with the lowest QALYs (0.028 & 0.022). Predictors identified that contributed to poorer HRQoL included age >60 years (β = -0.102), Length of stay (β = -0.019), Rural residence (β = -0.006), Stage IV of cancer (β = -0.014), Bloodstream infection (β = -0.038), and Urinary tract infections (β = -0.052), Use of Invasive devices (β = -0.055), Pneumonia (β = -0.137) and Sepsis (β = -0.274).

CONCLUSION:

Antimicrobial-resistant infections significantly impact HRQoL and QALYs in cancer patients compared with those with antimicrobial-sensitive infections and those without infections.

2026-09-01·JOURNAL OF DENTISTRY

Synbiotic–fluoride therapy as a next-generation non-invasive approach for early enamel lesions

Article

作者: Bijle, Mohammed Nadeem ; Kwok, Jonathan Chun Ming ; Yiu, Cynthia Kar Yung ; Abdallah, Mohamed Mahmoud ; Rajasekar, Vidhyashree ; Zaeneldin, Ahmed

OBJECTIVE:

To investigate the remineralization potential of a synbiotic-fluoride (SF) therapy combining l-arginine (Arg), sodium fluoride (NaF), and Lacticaseibacillus rhamnosus GG (LRGG) under a multi-species pH-cycling model.

METHODS:

Artificial enamel carious lesions were created on human enamel specimens and subjected to a 72-h pH-cycling protocol incorporating multi-species biofilm (Streptococcus mutans, Streptococcus sanguinis, and Streptococcus gordonii). Eight groups were assessed: control, 0.03%Arg, 0.22%NaF, LRGG, 0.22%NaF+0.03%Arg, 0.03%Arg+LRGG, 0.22%NaF+LRGG, and the SF therapy. Remineralization outcomes were quantified by mineral density (MD) and mineral gain (MG) assessments using micro-CT, SEM-EDX for Ca/P, change in surface nano-hardness (ΔSNH) and nanohardness recovery (SHR), and biochemical enamel calcium/phosphate content analysis.

RESULTS:

Post pH-cycling, SF therapy had the highest MD, MG, and % remineralization (p < 0.001). The SF therapy also exhibited the significantly highest Ca/P ratio on SEM-EDX (p < 0.001), along with the highest SNH, ΔSNH, and SHR , indicating superior remineralization than other groups (p < 0.001). Calcium and phosphate content further confirmed the enhanced remineralization potential of SF therapy. While dualagent combinations demonstrated greater remineralization than monotherapies, none matched the synergistic effect observed with the SF therapy.

CONCLUSIONS:

The combined application of Arg, F, and LRGG synergistically enhances enamel remineralization under dynamic biofilm-mediated conditions, outperforming both individual/combined treatment components.

CLINICAL SIGNIFICANCE:

Synbiotic-fluoride therapy represents a biofilm-mediated, noninvasive strategy for managing early enamel carious lesions, offering substantial advantages over fluoride alone. The therapy is aimed at high caries-risk individuals for primary and secondary caries prevention by promoting a biotic approach that ultimately aims to establish an eubiotic state.

项与 Arctigenin 相关的新闻（医药）

2026-06-23

·百度百家

RhodamineB-Arctigenin是一款罗丹明B荧光标记的牛蒡子苷元靶向荧光探针试剂

一、适合的场景 RhodamineB-Arctigenin是一款罗丹明B荧光标记的牛蒡子苷元靶向荧光探针试剂，将天然活性小分子Arctigenin与高荧光量子产率罗丹明B基团稳定偶联，兼具天然小分子生物活性与荧光可视化示踪功能。 1、细胞荧光成像与亚细胞定位场景：该试剂搭载罗丹明B高亮荧光基团，荧光信号稳定、背景噪音低、不易猝灭，可直接用于活细胞、固定细胞的荧光染色成像实验。能够精准示踪牛蒡子苷元小分子在细胞内的富集位置、分布规律与入胞效率，清晰展示药物在细胞核、细胞质、细胞器的靶向分布特征，完美解决天然小分子无法可视化定位的难题，广泛适配药物胞内定位分析、小分子入胞动态观测、药物蓄积特征研究等基础成像场景。 2、天然小分子药物机制与靶点验证场景：依托完整保留的牛蒡子苷元天然生物活性，该标记探针可完全模拟原药的细胞作用模式、抗炎抗氧化活性、肿瘤抑制功能，适用于牛蒡子苷元相关药理机制验证、信号通路研究、药物作用靶点筛查实验。可通过荧光信号强弱直观反馈药物结合效率、细胞摄取水平与药物作用浓度差异，帮助科研人员快速关联药物分布与药效结果，适配天然产物药理研究、活性机制分析、药物作用机理论证等科研场景。 3、药物筛选与分子互作检测场景：试剂荧光信号均一、特异性强、非特异吸附低，可适配高通量药物竞争筛选、小分子蛋白互作检测、药物结合亲和力分析等精细化实验。可用于对比不同干预条件下药物结合能力变化、筛选协同或拮抗药物、验证靶点蛋白结合特异性，同时兼容共聚焦显微成像、荧光定量分析、流式细胞检测等多类技术平台，适用于天然药物研发、先导化合物优化、靶向分子筛选等进阶科研场景。二、核心参数中文名称：罗丹明B标记牛蒡子苷元英文名称：RhodamineB-Arctigenin 外观：红色至玫红色粉末纯度：≥98%（HPLC检测合格，偶联均一、无游离荧光染料、无未标记母药、无降解杂质）包装规格：5mg、10mg、25mg 核心特性：罗丹明B高亮荧光、稳定荧光示踪、保留牛蒡子苷元生物活性、低非特异结合、成像稳定、适配定位与机制研究荧光特性：激发波长553nm，发射波长575nm，荧光信号稳定、抗猝灭能力强溶解性：易溶于DMSO、DMF、甲醇、乙醇等有机溶剂，适度溶于缓冲水溶液，溶液透亮无团聚，适配细胞成像、体外结合实验、荧光定量检测储存条件：-20℃干燥避光密封保存，低温运输，荧光基团与小分子偶联结构对强光、高温敏感，严禁反复冻融、长期光照，建议避光分装保存，保障荧光强度与分子活性稳定。三、相关试剂推荐 FINO2 (Ferroptosis inducer)（869298-31-7） Echinocandin B（54651-05-7） Pneumocandin B0（135575-42-7） GT115 Electrocompetent Cell Biotinyl-neuropeptide W-23 (human) Biotin-Gastrin Releasing Peptide, human TFA Biotin-Substance P（87468-58-4） DOTA-ECL1i DOTA-WC8 DOTA-TMVP1446（619300-53-7）本文由西安强化生物MG整理。科学探索，严谨为先；本产品仅用于科研，不用于人体临床应用。

2026-06-23

·搜狐新闻

RhodamineB-Arctigenin将天然活性小分子Arctigenin与高荧光量子产率罗丹明B基团稳定偶联

一、适合的场景 RhodamineB-Arctigenin是一款罗丹明B荧光标记的牛蒡子苷元靶向荧光探针试剂，将天然活性小分子Arctigenin与高荧光量子产率罗丹明B基团稳定偶联，兼具天然小分子生物活性与荧光可视化示踪功能。该试剂解决了天然牛蒡子苷元无荧光信号、无法原位追踪、胞内定位不明、分子互作难以观测的科研短板，适配多类可视化科研场景，是天然产物机制研究、药物示踪、靶点验证、细胞成像研究的高效工具试剂。 1、细胞荧光成像与亚细胞定位场景：该试剂搭载罗丹明B高亮荧光基团，荧光信号稳定、背景噪音低、不易猝灭，可直接用于活细胞、固定细胞的荧光染色成像实验。能够精准示踪牛蒡子苷元小分子在细胞内的富集位置、分布规律与入胞效率，清晰展示药物在细胞核、细胞质、细胞器的靶向分布特征，完美解决天然小分子无法可视化定位的难题，广泛适配药物胞内定位分析、小分子入胞动态观测、药物蓄积特征研究等基础成像场景。 2、天然小分子药物机制与靶点验证场景：依托完整保留的牛蒡子苷元天然生物活性，该标记探针可完全模拟原药的细胞作用模式、抗炎抗氧化活性、肿瘤抑制功能，适用于牛蒡子苷元相关药理机制验证、信号通路研究、药物作用靶点筛查实验。可通过荧光信号强弱直观反馈药物结合效率、细胞摄取水平与药物作用浓度差异，帮助科研人员快速关联药物分布与药效结果，适配天然产物药理研究、活性机制分析、药物作用机理论证等科研场景。 3、药物筛选与分子互作检测场景：试剂荧光信号均一、特异性强、非特异吸附低，可适配高通量药物竞争筛选、小分子蛋白互作检测、药物结合亲和力分析等精细化实验。可用于对比不同干预条件下药物结合能力变化、筛选协同或拮抗药物、验证靶点蛋白结合特异性，同时兼容共聚焦显微成像、荧光定量分析、流式细胞检测等多类技术平台，适用于天然药物研发、先导化合物优化、靶向分子筛选等进阶科研场景。二、核心参数中文名称：罗丹明B标记牛蒡子苷元英文名称：RhodamineB-Arctigenin 外观：红色至玫红色粉末纯度：≥98%（HPLC检测合格，偶联均一、无游离荧光染料、无未标记母药、无降解杂质）包装规格：5mg、10mg、25mg 核心特性：罗丹明B高亮荧光、稳定荧光示踪、保留牛蒡子苷元生物活性、低非特异结合、成像稳定、适配定位与机制研究荧光特性：激发波长553nm，发射波长575nm，荧光信号稳定、抗猝灭能力强溶解性：易溶于DMSO、DMF、甲醇、乙醇等有机溶剂，适度溶于缓冲水溶液，溶液透亮无团聚，适配细胞成像、体外结合实验、荧光定量检测储存条件：-20℃干燥避光密封保存，低温运输，荧光基团与小分子偶联结构对强光、高温敏感，严禁反复冻融、长期光照，建议避光分装保存，保障荧光强度与分子活性稳定。三、相关试剂推荐 FINO2 (Ferroptosis inducer)（869298-31-7） Echinocandin B（54651-05-7） Pneumocandin B0（135575-42-7） GT115 Electrocompetent Cell Biotinyl-neuropeptide W-23 (human) Biotin-Gastrin Releasing Peptide, human TFA Biotin-Substance P（87468-58-4） DOTA-ECL1i DOTA-WC8 DOTA-TMVP1446（619300-53-7）本文由西安强化生物MG整理。科学探索，严谨为先；本产品仅用于科研，不用于人体临床应用。返回搜狐，查看更多

100 项与 Arctigenin 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Arctigenin	B05XB01	DB00125

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胰腺癌	临床2期	日本	-	-
胰腺癌	临床2期	-	University of Toyama	-
胰腺癌	临床2期	-	Kracie Ltd.	-
年龄相关性黄斑变性	临床前	日本	Kracie Ltd.	2025-05-01
年龄相关性黄斑变性	临床前	日本	Gifu Pharmaceutical University	2025-05-01
骨肉瘤	临床前	中国	河南省洛阳正骨医院（河南省骨科医院）	2025-05-01
骨肉瘤	临床前	中国	西安交通大学医学院第二附属医院	2025-05-01
糖尿病肾病	临床前	中国	上海中医药大学附属龙华医院	2016-11-15
糖尿病肾病	临床前	-	Nephrology, Inc.	2016-11-15
炎症	临床前	美国	Icahn School of Medicine at Mount Sinai	2016-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


JPRN-UMIN000005787 (ASCO2013)	临床1期	胰腺癌	15	GBS-01 3g	餘襯範壓齋鑰淵鬱網憲(壓築衊鬱衊糧繭鹽鹹糧) = 襯積獵鏇觸醖築憲齋夢繭鹹襯遞網壓獵壓衊範 (鏇窪齋鬱選淵簾範範範 ) 更多	-	2013-05-20
				GBS-01 7.5g	餘襯範壓齋鑰淵鬱網憲(壓築衊鬱衊糧繭鹽鹹糧) = 壓鏇鏇鹹選範憲夢蓋艱繭鹹襯遞網壓獵壓衊範 (鏇窪齋鬱選淵簾範範範 ) 更多